Asosiy kontentga oʻtish
Maqola

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape

You ZhaiBeijing Institute of NeurosurgeryYicong DuDepartment of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, PR ChinaGuanzhang LiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR ChinaMingchen YuBeijing Institute of NeurosurgeryHuimin HuBeijing Institute of NeurosurgeryChangqing PanDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR ChinaDi WangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR ChinaZhongfang ShiDepartment of Pathophysiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR ChinaXu YanBeijing Institute of NeurosurgeryXuesong LiPeking University First HospitalTao JiangChinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, PR China. [email protected]Wei ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China. [email protected]
2023en
ABI

Annotatsiya

Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical response in treating both hematologic malignancies and solid tumors. Although instances of rapid tumor remissions have been observed in animal models and clinical trials, tumor relapses occur with multiple therapeutic resistance mechanisms. Furthermore, while the mechanisms underlying the long-term therapeutic resistance are well-known, short-term adaptation remains less understood. However, more views shed light on short-term adaptation and hold that it provides an opportunity window for long-term resistance. In this study, we explore a previously unreported mechanism in which tumor cells employ trogocytosis to acquire CAR molecules from CAR-T cells, a reversal of previously documented processes. This mechanism results in the depletion of CAR molecules and subsequent CAR-T cell dysfunction, also leading to short-term antigen loss and antigen masking. Such type of intercellular communication is independent of CAR downstream signaling, CAR-T cell condition, target antigen, and tumor cell type. However, it is mainly dependent on antigen density and CAR sensitivity, and is associated with tumor cell cholesterol metabolism. Partial mitigation of this trogocytosis-induced CAR molecule transfer can be achieved by adaptively administering CAR-T cells with antigen density-individualized CAR sensitivities. Together, our study reveals a dynamic process of CAR molecule transfer and refining the framework of clinical CAR-T therapy for solid tumors.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

3 ta iqtibos0 ta foydalanilgan manba